GlassScriptPhysician profile
Chang-Hoon Ahn
NPI 1558350827
$971.34
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $263 · 2021: $118 · 2022: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.24 | 2019-2022 | |
| Pfizer INC. | $161.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $103.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.75 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.84 | 2022 | |
| Abbvie INC. | $24.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.28 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.94 | 2022 | |
| Amgen INC. | $14.56 | 2019 | |
| Roche Diabetes Care, INC. | $13.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.44 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $13.26 | 2019 | |
| Daiichi Sankyo INC. | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chang-Hoon Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.